View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsGenocea Biosciences 過去の業績過去 基準チェック /06Genocea Biosciencesは13.2%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで33.8%毎年増加している。売上は成長しており、年平均40.6%の割合である。主要情報13.19%収益成長率32.93%EPS成長率Biotechs 業界の成長17.04%収益成長率40.62%株主資本利益率-300.29%ネット・マージン-1,946.15%前回の決算情報31 Mar 2022最近の業績更新Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesPrice Target Changed • Apr 27Price target decreased to US$5.74Down from US$6.74, the current price target is an average from 5 analysts. New target price is 1,300% above last closing price of US$0.41. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$0.48 last year.Price Target Changed • Apr 11Price target decreased to US$5.74Down from US$6.70, the current price target is an average from 5 analysts. New target price is 857% above last closing price of US$0.60. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.75 next year compared to a net loss per share of US$0.48 last year.Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.Price Target Changed • Mar 11Price target increased to US$7.67Up from US$6.68, the current price target is an average from 3 analysts. New target price is 555% above last closing price of US$1.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.98 last year.Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Jennifer Herron was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.分析記事 • Jun 17Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay PacketThe underwhelming share price performance of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) in the past three years would...Executive Departure • Apr 16Independent Director has left the companyOn the 12th of April, Ronald H. Cooper's tenure as Independent Director ended after 4.8 years in the role. We don't have any record of a personal shareholding under Ronald H.'s name. A total of 2 executives have left over the last 12 months.Recent Insider Transactions Derivative • Feb 21President exercised options to buy US$132k worth of stock.On the 17th of February, William Clark exercised options to buy 36k shares at a strike price of around US$2.24, costing a total of US$82k. This transaction amounted to 165% of their direct individual holding at the time of the trade. Since March 2020, William's direct individual holding has increased from 17.42k shares to 19.75k. Company insiders have collectively bought US$92k more than they sold, via options and on-market transactions, in the last 12 months.分析記事 • Feb 18What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Genocea Biosciences, Inc. ( NASDAQ:GNCA ) shareholders will doubtless be very grateful to see the share price up 77% in...Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Over the next year, revenue is expected to shrink by 67% compared to a 819% growth forecast for the Biotechs industry in the US.Is New 90 Day High Low • Feb 04New 90-day high: US$3.30The company is up 37% from its price of US$2.41 on 05 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.分析記事 • Jan 14How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?Every investor in Genocea Biosciences, Inc. ( NASDAQ:GNCA ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Dec 24New 90-day high: US$2.67The company is up 26% from its price of US$2.12 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 31New 90-day low: US$2.08The company is down 27% from its price of US$2.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.76 per share.Analyst Estimate Surprise Post Earnings • Oct 31Third-quarter earnings released: Earnings beat expectationsEarnings per share (EPS) surpassed analyst estimates by 69% at -US$0.08. Revenue is expected to shrink by 76% over the next year, compared to a 293% growth forecast for the Biotechs industry in the US.Major Estimate Revision • Oct 30Analysts increase EPS estimates to -US$1.07The 2020 consensus revenue estimate increased from US$922.4k to US$937.3k. Analysts raised their EPS forecasts from -US$1.21 to -US$1.07 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 6.3% next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is down by 8.6% to US$2.12 over the past week.Major Estimate Revision • Sep 18Analysts update estimatesThe 2020 consensus revenue estimate increased from US$722.4k to US$922.4k. Earning per share (EPS) estimate remained mostly unchanged at -US$1.21. The Biotechs industry in the US is expected to see a 17% decline in net income next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is up 17% to US$2.54 over the past week.収支内訳Genocea Biosciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:GNCA.Q 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 222-37154431 Dec 212-33154030 Sep 212-35153730 Jun 210-36153531 Mar 211-43153331 Dec 201-44143430 Sep 201-38143330 Jun 201-41133231 Mar 200-36123031 Dec 190-39122730 Sep 190-29122630 Jun 190-30132631 Mar 190-27142431 Dec 180-28142530 Sep 180-39145830 Jun 180-48145231 Mar 180-59134631 Dec 170-57133930 Sep 170-6215030 Jun 170-5815031 Mar 170-5415031 Dec 160-5015030 Sep 160-4415030 Jun 161-4115031 Mar 161-4015031 Dec 151-4214030 Sep 151-4413030 Jun 151-4312031 Mar 150-4011031 Dec 140-3510030 Sep 140-319030 Jun 140-278031 Mar 140-256031 Dec 131-225030 Sep 131-214030 Jun 131-204031 Mar 132-174031 Dec 122-1540質の高い収益: GNCA.Qは現在利益が出ていません。利益率の向上: GNCA.Qは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: GNCA.Qの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: GNCA.Qの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: GNCA.Qは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: GNCA.Qは現在利益が出ていないため、自己資本利益率 ( -300.29% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/05/23 21:27終値2023/05/23 00:00収益2022/03/31年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genocea Biosciences, Inc. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Michael UlzBairdMara GoldsteinCantor Fitzgerald & Co.Joseph PantginisH.C. Wainwright & Co.6 その他のアナリストを表示
Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target decreased to US$5.74Down from US$6.74, the current price target is an average from 5 analysts. New target price is 1,300% above last closing price of US$0.41. Stock is down 84% over the past year. The company is forecast to post a net loss per share of US$0.78 next year compared to a net loss per share of US$0.48 last year.
Price Target Changed • Apr 11Price target decreased to US$5.74Down from US$6.70, the current price target is an average from 5 analysts. New target price is 857% above last closing price of US$0.60. Stock is down 77% over the past year. The company is forecast to post a net loss per share of US$0.75 next year compared to a net loss per share of US$0.48 last year.
Reported Earnings • Mar 13Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: US$0.48 loss per share (up from US$0.98 loss in FY 2020). Net loss: US$33.2m (loss narrowed 24% from FY 2020). Products in clinical trials Phase I: 2 Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 77%. Over the next year, revenue is expected to shrink by 100% compared to a 60% growth forecast for the pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 42% per year, which means it is significantly lagging earnings.
Price Target Changed • Mar 11Price target increased to US$7.67Up from US$6.68, the current price target is an average from 3 analysts. New target price is 555% above last closing price of US$1.17. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.98 last year.
Board Change • Dec 06Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. Independent Director Jennifer Herron was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 30Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.082 loss in 3Q 2020)Third quarter 2021 results: Net loss: US$3.62m (loss narrowed 21% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
分析記事 • Jun 17Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay PacketThe underwhelming share price performance of Genocea Biosciences, Inc. ( NASDAQ:GNCA ) in the past three years would...
Executive Departure • Apr 16Independent Director has left the companyOn the 12th of April, Ronald H. Cooper's tenure as Independent Director ended after 4.8 years in the role. We don't have any record of a personal shareholding under Ronald H.'s name. A total of 2 executives have left over the last 12 months.
Recent Insider Transactions Derivative • Feb 21President exercised options to buy US$132k worth of stock.On the 17th of February, William Clark exercised options to buy 36k shares at a strike price of around US$2.24, costing a total of US$82k. This transaction amounted to 165% of their direct individual holding at the time of the trade. Since March 2020, William's direct individual holding has increased from 17.42k shares to 19.75k. Company insiders have collectively bought US$92k more than they sold, via options and on-market transactions, in the last 12 months.
分析記事 • Feb 18What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?Genocea Biosciences, Inc. ( NASDAQ:GNCA ) shareholders will doubtless be very grateful to see the share price up 77% in...
Analyst Estimate Surprise Post Earnings • Feb 12Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.9%. Earnings per share (EPS) exceeded analyst estimates by 2.9%. Over the next year, revenue is expected to shrink by 67% compared to a 819% growth forecast for the Biotechs industry in the US.
Is New 90 Day High Low • Feb 04New 90-day high: US$3.30The company is up 37% from its price of US$2.41 on 05 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 24% over the same period.
分析記事 • Jan 14How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?Every investor in Genocea Biosciences, Inc. ( NASDAQ:GNCA ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Dec 24New 90-day high: US$2.67The company is up 26% from its price of US$2.12 on 24 September 2020. The American market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 23% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 31New 90-day low: US$2.08The company is down 27% from its price of US$2.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$11.76 per share.
Analyst Estimate Surprise Post Earnings • Oct 31Third-quarter earnings released: Earnings beat expectationsEarnings per share (EPS) surpassed analyst estimates by 69% at -US$0.08. Revenue is expected to shrink by 76% over the next year, compared to a 293% growth forecast for the Biotechs industry in the US.
Major Estimate Revision • Oct 30Analysts increase EPS estimates to -US$1.07The 2020 consensus revenue estimate increased from US$922.4k to US$937.3k. Analysts raised their EPS forecasts from -US$1.21 to -US$1.07 in 2020. The Biotechs industry in the US is expected to see an average net income growth of 6.3% next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is down by 8.6% to US$2.12 over the past week.
Major Estimate Revision • Sep 18Analysts update estimatesThe 2020 consensus revenue estimate increased from US$722.4k to US$922.4k. Earning per share (EPS) estimate remained mostly unchanged at -US$1.21. The Biotechs industry in the US is expected to see a 17% decline in net income next year. The consensus price target of US$9.40 was unchanged from the last update. Share price is up 17% to US$2.54 over the past week.